[1] 国家药品监督管理局. 药品特别审批程序[EB/OL]. (2005-11-18)[2023-10-11]. https://www.nmpa.gov.cn/yaopin/ypfgwj/ypfgbmgzh/20051118010101724.html.
[2] 国家药品监督管理局. 总局关于解决药品注册申请积压实行优先审评审批的意见[EB/OL]. (2016-02-26)[2023-10-11]. https://www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjyp/20160226085101295.html.
[3] 国家药品监督管理局. 国家药监局关于发布《突破性治疗药物审评工作程序(试行)》等三个文件的公告(2020年第82号)[EB/OL]. (2020-07-08)[2023-10-11]. https://www.nmpa.gov.cn/xxgk/fgwj/ xzhgfxwj/20200708151701834.html.
[4] 国家市场监督管理总局.药品注册管理办法[EB/OL]. (2020-01-22)[2023-10-11]. https://www.gov.cn/zhengce/zhengceku/2020-04/01/content_5498012.htm.
[5] 吴忠虹, 董丽. 我国药品优先审评审批制度的现状分析[J]. 中国处方药, 2022, 20(10):29-31.
[6] 陈先红, 王闻雅. 新形势下我国药品特别审批制度的思考[J]. 中国食品药品监管, 2020(9):30-35.
[7] 国家药品监督管理局药品审评中心. 《药审中心加快创新药上市许可申请审评工作规范(试行)》[EB/OL]. (2023-03-31)[2023-10-11]. https://www.cde.org.cn/main/news/viewInfoCommon/ace377c025ad4f2bbf 94790673b2646e.
[8] FDA. Guidance for Industry: Expedited Programs for Serious Conditions–Drugs and Biologics[EB/OL]. (2014-05)[2023-10-11]. https://www.fda.gov/media/119748/download.
[9] FDA. Emergency Use Authorization[EB/OL]. (2017-01-13)[2023-10-11]. https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization.
[10] FDA. Emergency Use Authorization--Archived Information[EB/OL]. (2022-01-24)[2023-10-11]. https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization-archived-information.
[11] EMA. Conditional marketing authorisation–Report on ten years of experience at the European Medicines Agency[EB/OL]. (2017-01-23)[2023-10-11]. https://www.ema.europa.eu/system/files/documents/report/wc500219991_en.pdf.
[12] EMA. PRIME: Analysis of the first 5 years’ experience[EB/OL]. (2022-08-05)[2023-10-11]. https://www.ema.europa.eu/system/files/documents/report/2022-03_prime_5_years_report_updated_2022-04-05-en.pdf.
[13] PDMA. 先驱医药品审查认定制度[EB/OL]. (2020-12)[2023-10-11].https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryou/iyakuhin/tp150514-01_00001.html.
[14] PDMA. 医药品先驱审查认定制度的对象品目一览表[EB/OL]. (2023-06)[2023-10-11]. https://www.pmda.go.jp/files/000235895.pdf.
[15] PDMA. PMDA最新动向[EB/OL]. (2022-12-08)[2023-10-11].https://www.pmda.go.jp/files/000249287.pdf.
[16] 冯媛媛, 杨悦. 我国药品优先审评制度的实施情况及建议[J]. 中国药房, 2018, 29(15):2026-2031. doi:  10.6039/j.issn.1001-0408.2018.15.03
[17] 王颖, 张小平, 杨依晗, 等. 突发公共卫生事件下的药械紧急使用授权政策思考[J]. 中国医药导刊, 2020, 22(3):157-161.